EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have known clinical benefits in the treatment of EGFR-mutated NSCLC when compared to EGFR-WT NSCLC [6, 7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.